Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total sales.
| Website: | www.novartis.com |
| Email: | Investor.relations@novartis.com |
| Main Phone: | +41 613241111 |
| Address: | Lichtstrasse 35 |
| City / Town: | Basel |
| Country: | CHE |
| Postal Code: | 4056 |
| Exchange: | NYE |
| CEO: | Vasant Narasimhan |
| Employees: | 125161 |
| Issuer Type: | CS - Common Stock |
| Sector/Industry: | Cyclical |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
How do we say that a drug costs “too much” when it can save or significantly extend a person’s life?
80 million annual exams in the US involve mydriasis (pupil dilation)
First transdermal product for this fast growing generic manufacturer (Image: Amneal Pharmaceuticals).
NeuBase will capture Ohr's Nasdaq listing as it develops therapies for genetic diseases caused by mutant proteins.
Investing in early-stage biotechnology companies requires great skill and patience (luck is always helpful as well).
Financing supports near-term initiation of Phase 2 trials in essential tremor and spinocerebellar ataxia (Image: Cadent Therapeutics).
Currently enrolling Phase 3 patients for cord blood cell therapy with potential to be universal curative stem cell graft (Image: Gamida Cell)
RTB101 shown to decrease incidence of infection with severe symptoms by 52.1% vs placebo (Image: resTORbio)
Clinical candidates for reversal agent for antiplatelet drug and for pulmonary arterial hypertension (Image: PhaseBio Pharmaceuticals)
Phase 3 data shows siponimod has beneficial effects on disability, relapses and MRI disease activities (Image: Novartis)
Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total sales.
| Website: | www.novartis.com |
| Email: | Investor.relations@novartis.com |
| Main Phone: | +41 613241111 |
| Address: | Lichtstrasse 35 |
| City / Town: | Basel |
| Country: | CHE |
| Postal Code: | 4056 |
| Exchange: | NYE |
| CEO: | Vasant Narasimhan |
| Employees: | 125161 |
| Issuer Type: | CS - Common Stock |
| Sector/Industry: | Cyclical |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
How do we say that a drug costs “too much” when it can save or significantly extend a person’s life?
80 million annual exams in the US involve mydriasis (pupil dilation)
First transdermal product for this fast growing generic manufacturer (Image: Amneal Pharmaceuticals).
NeuBase will capture Ohr's Nasdaq listing as it develops therapies for genetic diseases caused by mutant proteins.
Investing in early-stage biotechnology companies requires great skill and patience (luck is always helpful as well).
Financing supports near-term initiation of Phase 2 trials in essential tremor and spinocerebellar ataxia (Image: Cadent Therapeutics).
Currently enrolling Phase 3 patients for cord blood cell therapy with potential to be universal curative stem cell graft (Image: Gamida Cell)
RTB101 shown to decrease incidence of infection with severe symptoms by 52.1% vs placebo (Image: resTORbio)
Clinical candidates for reversal agent for antiplatelet drug and for pulmonary arterial hypertension (Image: PhaseBio Pharmaceuticals)
Phase 3 data shows siponimod has beneficial effects on disability, relapses and MRI disease activities (Image: Novartis)
| Last Price 93.04 | Change $ 0.24 | Change % 0.26 | Tick N/A |
| Bid 92.69 | Bid Size 100.00 | Ask 93.16 | Ask Size 100.00 |
| Open 92.42 | High 93.15 | Low 92.42 | Prev Close 92.80 |
| Last Trade | Volume 3 mi | 52 Wk Hi 96.31 | 52 Wk Low 74.98 |
| Market Cap 210.7 bi | Ex-Div Date | Div Rate 2.83 | Yield 3.0460 |
| Shares 2,264,600,000.00 | EPS (TTM) 5.28 | PE Ratio 18.30 | Exchange NYSE |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 98 | 98 | 98 | 98 |
| Low Target Price Estimate | 82.3 | 82.3 | 82.3 | 82.3 |
| Mean Target Price Estimate | 90.77 | 90.77 | 90.77 | 90.15 |
| Standard Deviation | 7.92 | 7.92 | 7.92 | 11.1 |
| Date of Most Recent Estimate | 04/23/18 | 04/23/18 | 04/23/18 | 04/23/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 4 | 2018-06-01 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 6 | 2018-06-01 |
| SD | Specialized Disclosure Report | 8 | 2018-05-31 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 6 | 2018-05-18 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-17 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 5 | 2018-05-16 |
| 3 | Initial statement of beneficial ownership of securities | 1 | 2018-05-15 |
| SC TO-T/A | Amendment to a previously filed SC TO-T | 7 | 2018-05-15 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-14 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-11 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 |
| Moderate Sell | 1 | 1 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 |
| Mean Rec. | 2.8 | 2.8 | 2.8 | 2.5 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait